- Home
- RPTX vs IMMX Comparison
RPTX vs IMMX Comparison
Compare RPTX & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- IMMX
- Stock Information
- Founded
- RPTX 2016
- IMMX 2014
- Country
- RPTX Canada
- IMMX United States
- Employees
- RPTX N/A
- IMMX N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- RPTX Health Care
- IMMX Health Care
- Exchange
- RPTX Nasdaq
- IMMX Nasdaq
- Market Cap
- RPTX 63.9M
- IMMX 61.1M
- IPO Year
- RPTX 2020
- IMMX 2021
- Fundamental
- Price
- RPTX $1.56
- IMMX $2.71
- Analyst Decision
- RPTX Strong Buy
- IMMX Strong Buy
- Analyst Count
- RPTX 3
- IMMX 1
- Target Price
- RPTX $4.50
- IMMX $7.00
- AVG Volume (30 Days)
- RPTX 717.8K
- IMMX 204.0K
- Earning Date
- RPTX 08-05-2025
- IMMX 08-11-2025
- Dividend Yield
- RPTX N/A
- IMMX N/A
- EPS Growth
- RPTX N/A
- IMMX N/A
- EPS
- RPTX N/A
- IMMX N/A
- Revenue
- RPTX $1,073,000.00
- IMMX N/A
- Revenue This Year
- RPTX N/A
- IMMX N/A
- Revenue Next Year
- RPTX N/A
- IMMX N/A
- P/E Ratio
- RPTX N/A
- IMMX N/A
- Revenue Growth
- RPTX N/A
- IMMX N/A
- 52 Week Low
- RPTX $0.89
- IMMX $1.26
- 52 Week High
- RPTX $4.22
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- RPTX 58.19
- IMMX 53.07
- Support Level
- RPTX $1.37
- IMMX $2.74
- Resistance Level
- RPTX $1.68
- IMMX $3.20
- Average True Range (ATR)
- RPTX 0.08
- IMMX 0.21
- MACD
- RPTX 0.00
- IMMX -0.01
- Stochastic Oscillator
- RPTX 61.29
- IMMX 23.44
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.